Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 3 SUPPL. 59, 2010, Pages

  Furst, D E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pathogenesis; Radiographs; Rheumatoid arthritis; Symptoms; TNF inhibitors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR RISK; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; INFECTION RISK; INJECTION SITE REACTION; JOINT RADIOGRAPHY; LOADING DRUG DOSE; LYMPHOMA; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STANDING; TUBERCULOSIS; DRUG ANTAGONISM; DRUG COMBINATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956400778     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. FELDMANN M, BRENNAN FM, WILLIAMS RO et al.: Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res 1992; 4: 247-55.
2. MAINI RN, BRENNAN FM, WILLIAMS R et al.: TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993; 11 (Suppl. 8): S173-S175.
3. MAINI RN, ELLIOTT M, BRENNAN FM, WILLIAMS RO, FELDMANN M: Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 (Suppl. 11): S63-S66.
4. FELDMANN M, BRENNAN FM, WILLIAMS RO, ELLIOTT MJ, MAINI RN: Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. J Inflamm 1995; 47: 90-6.
5. CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-32.
6. NESTOROV I: Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol 2005; 74 (Suppl.): 13-18.
7. Remicade [prescribing information]. Malvern, PA: Centocor Ortho Biotech Inc.; 2009.
8. Enbrel [prescribing information]. Thousand Oaks, CA: Immunex Corporation; 2009.
9. Humira [prescribing information]. North Chicago, IL: Abbott Laboratories; 2009.
10. Simponi [prescribing Information]. Horsham, PA: Centocor Ortho Biotech Inc.; 2009.
11. ZHOU H, JANG H, FLEISCHMANN RM et al.: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007; 47: 383-96.
12. Cimzia [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
13. NESBITT A, FOSSATI G, BERGIN M et al.: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-232.
14. TRACEY D, KLARESKOG L, SASSO EH, SALFELD JG, TAK PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
15. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
16. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
17. KEYSTONE EC, GENOVESE MC, KLARESKOG L et al.: Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-96.
18. KEYSTONE E, VAN DER HEIJDE D, MASON D et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29.
19. SMOLEN JS, LANDEWE R, MEASE P et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
20. LIPSKY PE, VAN DER HEIJDE DMFM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
21. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
22. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
23. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
24. EMERY P, BREEDVELD FC, HALL S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
25. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
26. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
27. KLARESKOG L, VAN DER HD, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
28. VAN DER HEIJDE D, STRAND V, KEYSTONE E, LANDEWE R: Inhibition of radiographic progression by lyophilized certolizumab pegol added to methotrexate in comparison with methotrexate alone in patients with rheumatoid arthritis: The RAPID 1 trial. Arthritis Rheum 2007; 56 (Suppl.): 390-1.
29. EMERY P, FLEISCHMANN R, VAN DER HEIJDE D et al.: Golimumab and radiographic progression in rheumatoid arthritis: results of GO-BEFORE and GO-FORWARD studies. Arthritis Rheum 2009; 60 (Suppl.): S240.
30. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et ai: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
31. VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
32. FLEISCHMANN R, VENCOVSKY J, VAN VOLLENHOVEN R et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
33. HYRICH KL, SYMMONS DP, WATSON KD, SILMAN AJ: Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 1786-94.
34. WEAVER AL, LAUTZENHEISER RL, SCHIFF MH et al.: Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006; 22: 185-98.
35. KREMER JM, RITCHLIN C, MENDELSOHN A et al.: Golimumab, a new human anti-TNF□ antibody, administered intravenously in patients with active rheumatoid arthritis: 24-week efficacy and safety results of a phase 3, randomized, double-blind, placebo-controlled study. Presented at: EULAR 2009; June 10-13, 2009; Copenhagen, Denmark. Abstract OP-015.
36. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
37. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
38. ASKLING J, FORED CM, BRANDT L et al.: Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44.
39. ZINK A, ASKLING J, DIXON WG, KLARESKOG L, SILMAN AJ, SYMMONS DP: European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68: 1240-6.
40. WOLFE F, CAPLAN L, MICHAUD K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34.
41. SILMAN AJ, PETRIE J, HAZLEMAN B, EVANS SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-92.
42. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
43. BAECKLUND E, ILIADOU A, ASKLING J et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
44. ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
45. WOLFE F, MICHAUD K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9.
46. CARMONA L, DESCALZO MA, PEREZ-PAMPIN E et al.: All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5.
47. JACOBSSON LT, TURESSON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-18.
48. JACOBSSON LT, TURESSON C, NILSSON JA et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-5.
49. DIXON WG, WATSON KD, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
50. ALONSO-RUIZ A, PIJOAN JI, ANSUATEGUI E, URKAREGI A, CALABOZO M, QUINTANA A: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.
51. LAMOUR S, BRACHER M, NESBITT A: The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells. Ann Rheum Dis 2009; 68 (Suppl. 3): 188.
52. SAAG KG, TENG GG, PATKAR NM et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
53. COMBE B, LANDEWE R, LUKAS C et al.: EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45.
54. LUTT JR, DEODHAR A: Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008; 68: 591-606.
55. GENOVESE MC, COHEN S, MORELAND L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-19.
56. WEINBLATT M, COMBE B, COVUCCI A, ARANDA R, BECKER JC, KEYSTONE E: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807-16.